• Site Map
• Contact
• Help

• Login
• Residents
• About Us
• Career Center
• Patient Info
• Media Room
• My Profile
• Jobs at ACR

Useful Links

RTOG Study Shows Significantly Improved Survival for Prostate Cancer Patients Treated With Goserelin Adjuvant to Radiotherapy

April 1, 2005

PHILADELPHIA – Prostate cancer patients live longer when given goserelin immediately following radiotherapy, according to a new long-term study by the Radiation Therapy Oncology Group (RTOG), a clinical research component of the American College of Radiology (ACR). An article published in the April issue of the International Journal of Radiation Oncology Biology Physics details the 10-year results of a national multicenter clinical trial that enrolled nearly 1,000 patients with locally advanced prostate cancer. The RTOG study, one of the longest and largest studies of its type, concluded that administering goserelin following radiotherapy reduces the progression of prostate cancer and significantly improves survival.

"The RTOG results give increased hope to prostate cancer patients," comments Colleen Lawton, MD, of the Medical College of Wisconsin and a coauthor of the article. "Men diagnosed with prostate cancer can now expect to live longer and live a life free from a recurrence of their disease."

The RTOG study showed that the chance of survival 10 years after treatment was 10% higher for men who received goserelin immediately following their radiation therapy for locally advanced prostate cancer rather beginning hormonal therapy only upon tumor progression (49% vs 39%). Likewise, local progression was reduced from 38% to 22% for men receiving adjuvant goserelin.

Prostate cancer is the most commonly diagnosed cancer in men in the United States with over 230,000 new cases expected this year, and it is the second leading cause of death due to cancer. The RTOG study evaluated the effectiveness of administering goserelin to patients with prostate cancer treated with radiotherapy. Nearly one thousand (977) patients with locally advanced prostate cancer received either radiotherapy followed by monthly adjuvant goserelin (3.6 mg) or radiotherapy alone followed by observation and goserelin administration at relapse.

Goserelin
Goserelin, first introduced in 1987, is a luteinizing hormone-releasing hormone agonist (LHRHa) which reduces levels of sex hormones (testosterone in men and oestradiol in women) and is used to treat prostate cancer in men and hormone-dependent breast cancer in pre- and perimenopausal women.

Prostate Cancer
Prostate cancer is the presence of cancer cells in the prostate gland. It is the most commonly diagnosed male cancer in the United States, and is second only to lung cancer as a cause of cancer death. The prostate is a male sex gland that produces a thick fluid that forms part of semen. It is normally about the size of a walnut and is located below the bladder and in front of the rectum. Over 230,000 men in the United States will be diagnosed with prostate cancer this year, and of those, 30,000 are expected to die from their disease.

The manuscript, Androgen Suppression Adjuvant to Definitive Radiotherapy in Carcinoma of the Prostate – Long Term Results of Phase III RTOG 85-31, was published in the April 1, 2005, edition of the International Journal of Radiation Oncology Biology Physics, vol 61, pages 1285-1290. The independent study was coordinated by the RTOG, with participation from its member institutions. The National Cancer Institute provided financial support for the study and AstraZeneca provided the study drug, Zoladex®, for patients enrolled in the study.

Study authors include the following: Miljenko V. Pilepich, MD, from the University of California Los Angeles, Kathryn Winter, MS, from the American College of Radiology, Colleen A. Lawton, MD, from the Medical College of Wisconsin, Robert E. Krisch, from the University of Pennsylvania, Harvey B. Wolkov, MD, from Radiological Associates of Sacramento, Benjamin Movsas, MD, from Fox Chase Cancer Center, Eugen B. Hug, MD, from Dartmouth Hitchcock Medical Center, Sucha O. Asbell, MD, from Albert Einstein Medical Center in Philadelphia, and David Grignon, MD, from Wayne State University.

###

The Radiation Therapy Oncology Group (RTOG) is the clinical research component of the American College of Radiology (ACR), located in the ACR's Philadelphia office. The RTOG is a multi-institutional, international clinical cooperative group funded primarily by the National Cancer Institute. The RTOG has over 30 years of experience in conducting clinical trials and comprises over 250 major research institutions in the United States and Canada. The group currently is conducting more than 40 active studies that involve radiation therapy alone or in conjunction with surgery or chemotherapeutic drugs or which investigate quality-of-life issues and their effects on the cancer patient.

The American College of Radiology (ACR) is a national professional organization serving more than 32,000 radiologists, radiation oncologists, interventional radiologists and medical physicists with programs focusing on the practice of radiology and the delivery of comprehensive health care services.